First Line Ovarian Cancer Treatment - Cohort Study
The French cooperative group GINECO proposes to implement an observational study to describe a real situation, in daily practice tolerance and methods of administration of bevacizumab (Avastin ®)
Epithelial Ovarian Cancer
DRUG: Bevacizumab
Safety according to CTCAE v4.0 criteria, To assess patient safety and the tolerance of bevacizumab andministered regarding the daily practice of the oncologist., Patient will be followed dureing 36 months
Efficacy, • Evaluate the efficacy of bevacizumab (Avastin ®) in terms of progression-free survival (PFS) ., Patient will be followed during 36 months|Efficacy of treatment at relapse, Evaluate the efficacy of the treatment that will be administered at the disease relapse., Patient will be followed during 36 months|Characteristics of the population registered, Discribe the population that will be registered to make correlation with the safety and efficacy measure, At registration|Indication and cons indication of bevacizumab in clinical practice, Discribe the reason why patient receive or not bevacizumab in first line of ovarian cancer treatment, At registration|Evaluation of monitoring practices of bevacizumab, Discribe the method that are used during a treatment by bevacizumab in the daily practice, The patients will be followed during 36 months|Evaluation of the modality of use of bevacizumab, Discribe how bevacizumab is administered in the daily practice, The patients will be followed during 36 months
Population: Patients aged 18 years and older with an epithelial ovarian cancer, fallopian tube or primary peritoneal or witch it was decided to initiate a process comprising of Bevacizumab (Avastin ®) in first-line therapy